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studyquestion: Is the steroidhormoneproﬁle in follicular ﬂuid (FF) at the timeof oocyte retrieval different in naturallymatured follicles, as
in natural cycle IVF (NC-IVF), compared with follicles stimulated with conventional gonadotrophin stimulated IVF (cIVF)?
summaryanswer: Anti-Mullerian hormone (AMH), testosterone (T) and estradiol (E2) concentrations are3-fold higher, androstene-
dione (A2) is 1.5-fold higher and luteinizing hormone (LH) is 14-fold higher in NC-IVF than in cIVF follicles, suggesting an alteration of the
follicular metabolism in conventional gonadotrophin stimulated IVF.
what is knownalready: In conventional IVF, the implantation rate of unselected embryos appears to be lower than inNC-IVF,which
is possibly due tonegativeeffects of the stimulation regimenon follicularmetabolism. InNC-IVF, the intrafollicular concentrationofAMHhasbeen
shown to be positively correlated with the oocyte fertilization and implantation rates. Furthermore, androgen treatment seems to improve the
ovarian response in low responders.
studydesign, size, duration: This cross-sectional study involving 36NC-IVFand 40 cIVF cycleswasperformed from2011 to2013.
Within this population, 13 women each underwent 1NC-IVF and 1 cIVF cycle. cIVF was performed by controlled ovarian stimulation with HMG
and GnRH antagonists.
participants/materials, setting, methods: Follicular ﬂuid was collected from the leading follicles. AMH, T, A2, dehydroe-
piandrosterone (DHEA), E2, FSH, LHand progesterone (P)were determined by immunoassays in 76women.Aromatase activity in follicular ﬂuid
cells was analysed by a tritiated water release assay in 33 different women. For statistical analysis, the non-parametric Mann–WhitneyU orWil-
coxon tests were used.
main results and role of chance: In follicular ﬂuid from NC-IVF and from cIVF, median levels were 32.8 and 10.7 pmol/l for
AMH (P, 0.0001), 47.2 and 18.8 mmol/l for T (P, 0.0001), 290 and 206 nmol/l for A2 (P ¼ 0.0035), 6.7 and 5.6 pg/ml for DHEA (n.s.),
3292 and 1225 nmol/l for E2 (P, 0.0001), 4.9 and 7.2 mU/ml for FSH (P, 0.05), 14.4 and 0.9 mU/ml for LH (P, 0.0001) and 62 940 and
54 710 nmol/l for P (n.s.), respectively. Signiﬁcant differences in follicular ﬂuid concentrations for AMH, E2 and LH were also found in the 13
patients who underwent both NC-IVF and cIVF when they were analysed separately in pairs. Hormone analysis in serum excluded any relevant
impact of AMH, T, A2, and E2 serum concentration on the follicular ﬂuid hormone concentrations. Median serum concentrations were 29.4 and
0.9 mU/ml for LH (P, 0.0001) and 2.7 and 23.5 nmol/l for P (P, 0.0001) afterNC-IVF and c-IVF, respectively. Positive correlationswere seen
for FF-AMHwith FF-T (r ¼ 0.35,P ¼ 0.0002), FF-Twith FF-LH(r ¼ 0.48,P, 0.0001) andFF-E2with FF-T (r ¼ 0.75,P, 0.0001).Theanalysisof
aromatase activity was not different in NC-IVF and cIVF follicular cells.
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limitation, reasons for caution: Any association between the hormone concentrations and the implantation potential of the
oocytes could not be investigated as the oocytes in cIVF were not treated individually in the IVF laboratory. Since both c-IVF andNC-IVF follicles
were stimulated by hCG before retrieval, the endocrine milieu in the natural cycle does not represent the pure physiological situation.
wider implications of thefindings: The endocrine follicularmilieu and the concentration of putativemarkers of oocyte quality,
such as AMH, are signiﬁcantly different in gonadotrophin-stimulated conventional IVF compared with natural cycle IVF. This could be a cause for
the suggested lower oocyte quality in cIVF comparedwith naturally matured oocytes. The reasons for the reduced AMH concentrationmight be
low serum and follicular ﬂuid LH concentrations due to LH suppression, leading initially to low follicular androgen concentrations and then to low
follicular AMH production.
study funding/competing interests: Funding for this study was obtained from public universities (for salaries) and private in-
dustry (for consumables). Additionally, the study was supported by an unrestricted grant from MSD Merck Sharp & Dohme GmbH and IBSA
Institut Biochimique SA. The authors are clinically involved in low-dose monofollicular stimulation and IVF therapies, using gonadotrophins
from all gonadotrophin distributors on the Swiss market, including Institut Biochimique SA andMSDMerck Sharp &Dohme GmbH.Otherwise,
the authors have no competing interests.
trial registration number: Not applicable.
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Introduction
Ever since gonadotrophins were introduced into IVF treatment, it has
been discussed whether they might have an effect on follicular metabol-
ism, and thereby affect the success rate of IVF therapies. This discussion
has been further intensiﬁed by recent studies proposing co-treatment
with androgens to modify the endocrine system in IVF therapies.
These newco-treatments are based on studies providing some evidence
that the IVF outcome is inﬂuenced by the kind of gonadotrophins being
used.
In large clinical studies however, it has been shown that HMG, rFSH
and rFSH+LH only show marginal differences in the pregnancy rate
per collected oocyte (Andersen et al., 2006; Durnerin et al., 2008).
Despite this, exogenous LH activity in a cycle stimulated with HMG or
rFSH+LH seems to have a positive effect on the development of top-
quality embryos (Lisi et al., 2005; Andersen et al., 2006).
These studies suggest that the gonadotrophins used might affect the
outcome of IVF therapies as the gonadotrophins have a direct effect
on the follicular metabolism. However, analysing the effect of different
gonadotrophins is hardly possible as a large number of cases are neces-
sary to detect a signiﬁcant differencewhen applying the pregnancy rate as
a primary end-point. Furthermore, a subtle dysregulation in folliculogen-
esis can hardly be discovered using the pregnancy rate as an end-point.
Therefore, the analysis of the follicular endocrine milieu has been
chosen in some studies to identify follicular markers for the effect of
stimulation treatments and oocyte quality.
Intrafollicular AMH, measured at the time of follicular aspiration in
conventional gonadotrophin-stimulated IVF therapies (cIVF), has been
identiﬁed as a marker for oocyte implantation potential. In several
studies, high AMH concentrations have correlated with the pregnancy
rate (Fanchin et al., 2007; Takahashi et al., 2008; Pabuccu et al., 2009).
However, the investigation of the mechanisms which stimulate AMH
production has only been rudimentally investigated to date. By compar-
ing various cIVF stimulation regimens, Andersen and Lossl (2008) sug-
gested that AMH secretion was stimulated by a HCG-induced, high
follicular androgen concentration. These results again raise the question
of whether the suppression of endogenous LH, which is achieved in cIVF
by the use of GnRH agonists and antagonists, reduces thecal cell andro-
gen production and therefore the androgen concentration in the follicu-
lar ﬂuid. The consequence could be a reduced AMH production, which
directly or indirectly leads to reduced oocyte quality. Despite this, there
is a lack of conclusive studies to demonstrate any effect of the type and
dose of gonadotrophin stimulation on follicle metabolism and therefore
on the oocyte quality in conventional IVF.
Thus the comparison of the endocrinemilieu of naturally matured fol-
licles with follicles after high-dose gonadotrophin stimulation allows new
insights into theeffect of gonadotrophinson follicular physiology.The fol-
licular ﬂuid fromnatural cycle IVF (NC-IVF) follicles can be considered to
be a model for the ideal follicle as evolution has probably perfected folli-
culogenesis and everyendocrinemanipulation is likely to demonstrate an
adverse disruption of the endocrine milieu. This concept is also sup-
ported by the discovery that when the follicle matures naturally, as in
natural cycle IVF, higher implantation rates are achieved than with con-
ventional IVF (Aanesen et al., 2010).
Therefore, in this study, we compared the endocrinemilieu inNC-IVF
with that of cIVF and investigated the concentrations of AMH, androgens
and gonadotrophins in serum and follicular ﬂuid at the time of follicular
aspiration. Theendocrinemilieu of naturallymatured, and therefore sup-
posedly ideal, follicles is thereby characterized and the effects of high-
dose gonadotrophin stimulation on the endocrine milieu are described.
Materials andMethods
In this study, 76patientsunderwent1NC-IVF (n ¼ 36) and/or1cIVF (n ¼ 40)
cycle and 13 among them were treated with both therapies. Aromatase
assays were performed with another set of 33 patients (NC-IVF n ¼ 15;
cIVF n ¼ 18). The study was approved by the local ethical committee and
each patient’s approval was given by written consent.
cIVF patients were stimulated with HMG (150–300 IU per day of human
menopausal gonadotrophin, Menogon HPw, Ferring AG, Baar, Switzerland)
which was initiated between Day 3–5 of themenstrual cycle. GnRH antago-
nists (Orgalutranw, MSD Merck Sharp & Dohme GmbH, Lucerne, Switzer-
land) were ﬁrst administered between Day 6 and 7 of the menstrual cycle
and continued until ovulation induction.Once an adequate ovarian response
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had been conﬁrmed, 10 000 IU of urinary human chorionic gonadotrophin
(hCG) (Predalonw, MSD Merck Sharp & Dohme GmbH, Lucerne, Switzer-
land) was administered to induce ovulation. Transvaginal oocyte retrieval
was scheduled 36 h after hCG administration and performed under
general anaesthesia. To minimize contamination with blood and to reduce
cross contamination from other follicles, follicular ﬂuid was collected
only from the ﬁrst follicle aspirated. The follicle chosen was at least 18 mm
in diameter.
NC-IVF patients were monitored by ultrasound and analysis of luteinizing
hormone (LH) and 17b-estradiol (E2) concentrations. When the follicle
diameter reached at least 18 mm and E2 concentration was .800 pmol/l,
5000 IU of hCG was administered and oocyte retrieval was performed
without anaesthesia 36 h later.
For both types of cycle, the cumulus oophorus complex was isolated and
the follicular ﬂuid was clariﬁed by centrifugation, ﬁrstly at 600 × g for 10 min
and then followed by a second 10 min centrifugation at 1300 × g. The super-
natant ﬂuids were stored at2308C until further analysis. Venous blood was
collected at the time of follicle aspiration and the obtained serumwas stored
at 2308C.
We intended to analyse a broad spectrum of those hormones which
stimulate the follicles, such as FSH and LH, and those which are produced
in response by thecal and granulosa cells or which are metabolized in the
process of follicular hormone production. Testosterone (T), follicle stimulat-
ing hormone (FSH), progesterone (P) in serum and follicular ﬂuid, and serum
E2 concentrations were analysed by electrochemiluminescent immunoassay
(ECLIA) on aCOBAS 6000 (e601Modul) (RocheDiagnostics GmbH,Mann-
heim,Germany). The inter-assaycoefﬁcients of variation (CV)of these assays
were,4%.Dehydroepiandrosterone (DHEA)wasmeasuredwith an ELISA
from IBL (IBL-International, Hamburg, Germany). The inter-assay CV of this
testwas,12%. Androstenedione (A2) was analysed by radio-immunoassay
(RIA, Coat-a-countw, Siemens Healthcare Diagnostics, Inc., Los Angeles,
CA, USA). This method was also used for the determination of E2 in the fol-
licular ﬂuid as it required a 1:500 dilution. TheCVof these RIAswere,11%.
AMH and LHwere determined manually with commercially available micro-
plate enzyme immunometric methods (ELISA). The assay for AMH was
obtained from Immunotech (Marseille, France). Both sera and follicular
ﬂuidswere introducedwithout dilution and the protocol of themanufacturer
was followed. The inter-assayCVwas,14.2%.Themethod used for the de-
termination of LH was from Cayman, Ann Arbor, MI, USA. Serum was used
directly in the assay, as recommended by the manufacturer. Follicular ﬂuid
was similarly used without dilution since the expected concentrations were
lower (but still above the sensitivity limit of 0.5 mIU/ml). The inter-assay
CV was ,7.9%.
For aromatase activity measurements, follicular aspirates were each
centrifuged at 1000 × g for 5 min and then stored at 2408C. After
thawing, the material was again centrifuged, the supernatant discarded and
the cell pellet was redissolved in KiP buffer before it was vortexed vigorously.
Aromatase activity measurements were then performed by the tritiated
water release assay as described elsewhere (Lephart and Simpson, 1991;
Pandey et al., 2007) on this material. In brief, reactions were performed at
378C in 15-ml Falcon tubes each with a ﬁnal volume of 200 ml consisting of
176 ml cell lysate and 10 nM androstenedione labelled with [1b-3H(N)]-
androstene-3,17-dione (30 000 cpm/reaction) in 50 mM K-phosphate
buffer (pH 7.4). The reactions were initiated by adding 1 mM NADPH and
stopped by adding 1 ml of chloroform. After vortexing for 30 s, 1 ml of
water was added, and the mix was centrifuged at 1000 rpm for 5 min.
Aliquots (0.5 ml) of the water phase were extracted with an equal volume
of 5% charcoal/0.5% dextran for 40 s, then centrifuged at 12 000 rpm for
15 min, and 0.5-ml aliquots of supernatants were collected for counting of
3H radioactivity. The conversion rate of androstenedione to estrone was
assessed for both groups. For the internal control purposes, total protein
contents of the follicular cell material (as used for the aromatase assay)
was measured in each sample by a modiﬁed Lowry assay according to the
manufacturer’s protocol (DC Protein Assay, Bio-Rad Laboratories AG,
Cressier, Switzerland).
Statistical analyses were performed by the non-parametrical Mann–
Whitney U-test for the comparison of hormone levels between the two
patient groups. Regression analyseswere done using the Spearman rank cor-
relation method. P-values ,0.05 were considered as statistically signiﬁcant.
Results
The mean patient ages were 34.9 years (SD 4.9, range 21–42) for the
NC-IVF group and 33.8 years (SD 3.7, range 25–41) for the cIVF
group. The mean follicle sizes at the time of aspiration in the NC-IVF
andc-IVF groupswere19.6 mm(SD1.2) and19.5 mm(SD1.2), respect-
ively (Table I). Both parameters, as well as the AMH serum concentra-
tions, were not signiﬁcantly different between the two groups. The
mean ages of the additional set of patients for the aromatase assay
were 36.1 years (SD 4.4, range 27–42) for the NC-IVF group and 35.5
years (SD 3.8, range 27–42) for the cIVF group (Table IV).
.............................................................................................................................................................................................
Table I Characteristics of trial participants for follicular ﬂuid hormone assays.
NC-IVFa cIVFb NC-IVF1 cIVFc
(n5 36) (n5 40) (n 5 13)
Mean age (years) 34.9 (+4.9, 21–42) 33.8 (+3.7, 25–41) 37.2 (+4.3, 31–42)
Aetiology of infertility (n/total)
Male factor 28/38 23/40 7/13
Tubal factor 5/38 4/40 2/13
Endometriosis 0/38 0/40 0/13
Idiopathic 2/38 1/40 1/13
Others 3/38 12/40 3/13
Anti-Mullerian hormone (pmol/l) 17.7 (+14.6) 22.9 (+15.3) 17.3 (+8.9)
Mean follicle size (mm) 19.6 (+1.2) 19.5 (+1.2)
aNatural cycle IVF.
bConventional gonadotrophin-stimulated IVF.
cSubgroup of patients, undergoing both therapies.
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In addition to follicular ﬂuid, serum was analysed to exclude any rele-
vant impact of serum concentrations on the difference of follicular ﬂuid
protein concentrations in follicles from NC-IVF and cIVF. The relevant
impact from the hormones present in the circulation could be excluded
for AMH, T, A2 and E2 as the follicular ﬂuid concentrations were higher
than that found in serum (Table II).
For DHEA, FSH and LH concentrations were similar or even higher in
serum than in follicular ﬂuid, suggesting that follicular ﬂuid concentrations
of these hormones are strongly inﬂuenced by serum.
In the follicular ﬂuid, AMH, T, A2, E2 and LH concentrations were sig-
niﬁcantly different in NC-IVF compared with that in c-IVF follicles
(Table II). The results for these six parameters are given in Fig. 1 as
box andwhisker plots, illustrating the variations of the individual concen-
trations. AMH, T and E2 concentrations were 3-fold higher, A2 was
1.5-fold higher and LHwas14-fold higher inNC-IVF than in cIVF fol-
licles. A subgroup analysis of those patients, receiving both therapies
(n ¼ 13), conﬁrmed the signiﬁcant differences in the concentrations of
AMH, E2 and LH between NC-IVF and cIVF follicles (Table III).
Progesteroneconcentrationswere similar inNC-IVFandcIVF follicles.
However, the serumconcentrationsweremarkedlydifferent. InNC-IVF,
serum concentrations were 2.7 nmol/l and in cIVF, serum concentra-
tions were 23.5 nmol/l at the time of follicle aspiration (Fig. 2).
The markedly increased concentration of the putative implantation
markerAMH inNC-IVF follicles raised thequestionwhether theconcen-
tration of AMH would correlate with other follicular ﬂuid and serum
parameters and thus suggest a metabolic link. Therefore a regression
analysis of AMH and testosterone was performed. As shown in Fig. 3B
testosterone concentrations were positively correlated (r ¼ 0.35, P ¼
0.0002) with AMH concentrations.
The signiﬁcantly increased testosterone concentration in NC-IVF fol-
licles might be either due to increased testosterone production due to
increased LH activity in NC-IVF or due to an inhibition of the follicular
aromatase, inhibiting the conversionofT into E2.An inhibitionof the aro-
matase activity, i.e. a reduced conversion of T into E2 seems to be unlike-
ly as such an effectwould result in an accumulation of testosteronewith a
non-linear correlationofT andE2 andnot a linear correlation as shown in
Fig. 3. Furthermore, aromatase activitieswere similar inNC-IVF and cIVF
follicular cells as analysed by tritiated water release assays. NC-IVF fol-
licular cells showed a conversion rate of 1360+277 arbitrary units
(au) and cIVF follicular cells showed a conversion rate of 1144+182
au (P ¼ 0.23) (Table IV).
The alternative concept, a link between testosterone production and
LH activity inNC-IVF follicles, was supported by a positive correlation of
testosterone and LH concentrations (r ¼ 0.48, P, 0.0001).
Discussion
Our study describes the endocrine proﬁle of follicles which were,
apart from the ovulation induction with hCG, naturally matured.
We assume that these entities represent an evolutionary model of
the ideal follicle. Naturally matured follicles may accordingly generate
the highest implantation potential for the embryo derived from the
oocyte they are harbouring.
Our study compared the endocrine proﬁle of naturally matured
(NC-IVF) follicles with that of follicles generated after conventional high-
dose gonadotrophin stimulation using LH-suppressing GnRH antago-
nists (cIVF). This comparison referred to a study group of 76 different
subjects in both treatment groups and a sub-analysis with 13 subjects
who underwent both therapies to minimize intra-individual variation.
The results in the small subgroup were largely identical to those in the
complete, cross-sectional treatment groups.
For the analysis, we chose hormones which reﬂect the steroidmetab-
olism in the follicle. In theca cells, LH induces the conversion of pregne-
nolone into progesterone orDHEAwhich is then converted into A2 and
T. A2 and T are transported to the granulosa cells where they are con-
verted under the inﬂuence of FSH by the enzyme aromatase into E2.
AMH is also producedby granulosa cells and large amounts of progester-
one are synthesized by luteinized granulosa and thecal cells.
The main differences in the comparison of NC-IVF and cIVF were the
signiﬁcantly lower intrafollicularAMHconcentrations, androgenconcen-
trations and LH concentrations in the cIVF follicles. In addition, serum
progesterone concentrations were much lower in NC-IVF cycles.
AMHhas alreadybeen identiﬁed as amarker for ahighoocyte implant-
ation potential in several studies (Fanchin et al., 2007, Takahashi et al.,
2008; Pabuccu et al., 2009). Therefore, this means that the oocyte
quality in naturally matured follicles might be higher when compared
with cIVF as higher AMH concentrations were measured for NC-IVF.
Various studies support this theory. Implantation rates of 25% have
......................................................................... ........................................................................
.............................................................................................................................................................................................
Table II Concentrations of various hormones in follicular ﬂuid and serum on the day of oocyte retrieval in all natural cycle
(NC-IVF) and conventional gonadotrophin-stimulated (cIVF) IVF cycles (cross-sectional analysis).
Hormone Follicular fluid concentration Serum concentration
NC-IVF (n 5 36) cIVF (n 5 40) P-value NC-IVF (n 5 30) cIVF (n 5 33) P-value
AMH (pmol/l) 32.8 (0.5–281) 10.7 (1.0–238) ,0.0001 17.2 (3.7–66.4) 12.7 (4.5–68.0) 0.0287
Testosterone (mmol/l) 47.2 (1.5–.52) 18.8 (2.8–,52) ,0.0001 1.0 (0.1–3.2) 2.0 (0.6–4.1) ,0.0001
A2 (nmol/l) 290 (8.0–.350) 206 (29–.350) 0.0035 9.8 (4.2–29.4) 14.5 (5.8–47.0) 0.0003
DHEA (pg/ml) 6.7 (2.3–16.7) 5.6 (1.4–13.0) 0.0744 6.3 (2.8–12.6) 5.2 (2.3–12.0) 0.2305
E2 (nmol/l) 3292 (369–7153) 1225 (109–5020) ,0.0001 0.6 (0.2–5.3) 4.0 (0.4–10.7) ,0.0001
FSH (mIU/ml) 4.9 (0.2–15.6) 7.2 (1.3–17.3) 0.0414 11.8 (5.2–39.7) 11.1 (2.7–18.1) 0.3604
LH (mIU/ml) 14.4 (0.3–60.0) 0.9 (0.2–12.2) ,0.0001 29.4 (10.5–81.9) 0.9 (,0.2–9.8) ,0.0001
The results are given as median and range. P-values were obtained by non-parametrical Mann–Whitney U-test.
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been described for NC-IVF (Aanesen et al., 2010), whereas for cIVF
without embryo selection they are only 15% (DIR, FIVNAT).
However, it must be stressed that a comparison of studies with
data from large registers is only possible to a limited extent and a
correct comparison as part of a randomized study had not been
carried out to date. Nevertheless, the increased AMH concentrations
in naturally matured follicles were conﬁrmed and cannot be due to
the different stages of follicle maturation as previously suggested
Figure 1 Tukey Box andWhisker plot of those hormones in the follicular ﬂuid in natural cycles (NC-IVF, n ¼ 36, ﬁne lines) and conventional gonado-
trophin stimulated IVF cycles (cIVF, n ¼ 40, bold lines) which showed signiﬁcantly different concentrations (Table II). Boxes represent the 25th and 75th
centiles, and thebottomand topwhiskers aredeﬁnedby the25th centileminus 1.5 times the interquartile range (IQR) and the75th centile plus 1.5 times the
IQR, respectively. Data points outside this range are plotted as individual points. Please note the logarithmic scale.
......................................................................... .....................................................................
.............................................................................................................................................................................................
Table III Subanalysis of follicular ﬂuid and serum hormone concentration of those 13 patients undergoing both a natural
cycle (NC-IVF) and a conventional gonadotrophin-stimulated (cIVF) IVF cycle (paired analysis).
Hormone Follicular fluid concentration (n 5 13) Serum concentration (n 5 7)
NC-IVF cIVF P-value NC-IVF cIVF P-value
AMH (pmol/l) 35.0 (0.5–281) 10.4 (6.8–16.8) 0.0134 18.7 (9.5–42.8) 7.5 (5.4–17.3) 0.0156
Testosterone (mmol/l) 47.2 (1.5–.52) 25.4 (5.4–.52) 0.1016 0.8 (0.1–1.2) 1.5 (0.6–2.6) 0.0313
A2 (nmol/l) 228 (8.0–.350) 246 (36–.350) 0.5186 8.1 (4.2–12.4) 11.8 (5.8–16.3) 0.1094
DHEA (pg/ml) 5.6 (2.3–13.9) 6.8 (3.0–13.0) 1.0 6.5 (3.0–12.0) 6.3 (3.6–8.1) 1.0
E2 (nmol/l) 2948 (369–7153) 1768 (320–5020) 0.0327 0.6 (0.2–1.3) 3.7 (1.1–8.3) 0.0156
FSH (mIU/ml) 5.0 (0.2–12.8) 8.4 (1.9–15.8) 0.2163 13.3 (10.4–39.7) 13.0 (8.8–15.1) 0.1875
LH (mIU/ml) 16.3 (0.3–60.0) 0.6 (0.2–6.2) 0.0012 40.2 (22.1–77.6) 0.9 (0.5–2.0) 0.0156
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Figure2 Progesterone concentration in the follicular ﬂuid in natural cycles (NC-IVF, n ¼ 36, ﬁne lines) and conventional gonadotrophin stimulatedcycles
(cIVF, n ¼ 40, bold lines). The data are presented according to Fig. 1.
Figure 3 Correlations between different hormones in follicular ﬂuid of natural cycle (NC-IVF, open circles) and conventional gonadotrophin stimulated
(cIVF, closed circles) IVF cycles. (A) estradiol as a function of testosterone; (B) AMHas a function of testosterone; (C) testosterone as a function of LH. The
dotted vertical or horizontal line in each graph represents themaximum testosterone concentration which could be quantiﬁed (52.2 mmol/l). Please note
the logarithmic scale. The dashed regression line shown pertains to the total patient population (NC-IVF plus cIVF).
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(Fanchin et al., 2005) because the mean size of the follicles in the groups
compared was identical.
While higher AMH concentrations in NC-IVF follicles could be the
reason for the higher oocyte quality, leading to higher implantation
rates in NC-IVF cycles, it cannot be ruled out that other factors might
be involved.One of these factors could be the serumprogesterone con-
centration, which we found to be nine times higher in cIVF compared
with NC-IVF at the time of oocyte aspiration, 1.5 days after hCG appli-
cation. A meta-analysis (Kolibianakis et al., 2012) has shown that high
serum progesterone concentrations at the time of hCG application cor-
relate with lower pregnancy rates per cycles. However, these ﬁndings
have recently been questioned by a pooled analysis (Griesinger et al.,
2013) which differentiated between low, normal and high responders
and thereby did not ﬁnd an impact of high progesterone concentrations
onpregnancy rates. Furthermore, these studieswere focusedonproges-
terone concentrations at the time of hCG application. Data about the
outcome in relation to serum progesterone concentrations at a later
stage are very sparse and not conclusive (Check et al., 2008). Therefore,
it seems plausible that rather than serum progesterone concentrations,
the follicular endocrine milieu itself is responsible for the higher implant-
ation rate in the naturally matured follicle.
Three essential questions can be derived from these results related to
the follicular endocrinemilieu. (i)What is the signiﬁcanceof the increased
AMH concentrations? (ii) Which regulatory mechanisms lead to the
increased AMH concentrations? And (iii) Is it possible to draw conclu-
sions for conventional IVF stimulation?
The ﬁrst question, the signiﬁcance of follicular AMHonoocyte quality,
is difﬁcult to answer as the signiﬁcance of AMH is still unclear. It has only
been shown that AMH is produced by granulosa cells (Vigier et al., 1984)
and that atretic granulosa cells do not produce AMH (De Vet et al.,
2002). The degree of apoptosis in granulosa cells correlates with the de-
velopmental competence of the oocyte (Nakahara et al., 1997). These
relationships lead to the hypothesis that a high AMH concentration
may have no direct effect on the oocyte, but is amarker for the granulosa
cell function, and as such is of relevance for the function of the oocyte. In
contrast, it has been suggested that there is a direct link in the opposite
directionbetweenoocyte function and intrafollicularAMHproductionof
the granulosa cells. The oocyte seems to activate various physiological
processes in the surrounding granulosa cells. In mice, it has been
shown that the oocyte inﬂuences the AMH expression via this mechan-
ism (Salmon et al., 2004).
The secondquestion,which regulatorymechanisms leads to theAMH
production, is similarly difﬁcult to address. It has been shown that during
IVF treatment, induction with hCG before gonadotrophin stimulation
leads to higher intrafollicular androgen concentrations as well as
increased follicular AMH concentrations (Andersen and Lossl, 2008).
It was suggested that intrafollicular testosterone possibly stimulates the
AMH production. Based on our study results, this means that the
increased androgen concentrations in the naturally matured follicles
would be the reason for the increased AMH concentrations. The
precise mechanisms for the stimulation of AMH production are,
however, still unknown.Androgensmay induceFSHreceptorexpression
in the granulosa cells (Weil et al., 1999). A direct stimulatory effect of LH
is also possible as a stimulatory effect of hCG/LH on the AMH produc-
tion in granulosa cells of PCO patients, but not in the granulosa cells of
healthy women, has been found (Phy et al., 2004). In our study, we
detected acorrelationbetween the follicular testosteroneconcentration
and theAMHconcentration,which supports but doesnot prove the sup-
position of a dependencyof theAMHconcentration on the testosterone
concentration.
This in turn raises the question of whichmechanismswould lead to an
increased follicular testosterone concentration in naturally matured fol-
licles. Elevated androgen levels can be the consequence of two different
mechanisms. Either AMH inhibits the aromatase, as a result of which
androgens accumulate, or androgenesis is stimulated by increased
LH-mediated stimulation of theca cells.
One study in which an in vitro inhibition of aromatase by AMH was
detected, speaks in favour of the aromatase inhibition hypothesis (Gross-
manetal., 2008).However theresultsofour studyargueagainst thishypoth-
esis. Inhibition of aromatase would rather lead to an increase in the
testosterone/estradiol ratio. But this ratio was not increased in the follicles
with an increased AMH concentration (Fig. 3). Furthermore, the analysis of
aromatase activity revealed similar activity inNC-IVFand cIVF follicular cells.
Thesecondhypothesis implies that androgensynthesis is increased innat-
urally matured follicles due to an increased stimulation of theca cells by LH.
Indeed, we found higher LH concentrations in serum as well as in follicular
ﬂuid in naturallymatured follicles, because LH suppression usingGnRHago-
nists or GnRH antagonists, as in cIVF, is not performed in NC-IVF.
From this comes the third question of whether conclusions for con-
ventional IVF stimulation could be drawn from the study results. Assum-
ing that high intrafollicular AMH concentrations are a marker for high
oocyte quality, stimulation processeswhich lead to high intrafollicular an-
drogen concentrations, and consequently to high AMH concentrations,
would be beneﬁcial. Accordingly this could be achieved with a sufﬁcient
level of theca cell stimulation by LH, either by reduced suppression of the
physiologically endogenous pituitary LH secretion or by exogenous LH
supplementation with HMG or LH.
In linewith this hypothesis, a comparison of IVF stimulationwithHMG
versus rFSHhas shown thatHMGstimulation signiﬁcantly increased con-
centrations of intrafollicular testosterone and estradiol (Smitz et al.,
2007). The ongoing implantation rate was 24% after HMG stimulation
compared with 20% after rFSH stimulation (P ¼ 0.25) (Andersen et al.,
2006). In a comparison of stimulation with rFSH versus rFSH plus rLH,
a meta-analysis of ﬁve studies showed a signiﬁcantly higher number of
mature oocytes with LH-supplementation (P ¼ 0.0098) but no signiﬁ-
cant differences in the implantation rate (Barufﬁ et al., 2007).
Inwomen aged≥35 years, the implantation rate under the addition of
rLHwas shown tobe signiﬁcantly increased in ameta-analysiswith anOR
........................................................................................
Table IV Characteristics of trial participants and
aromatase activity in follicular ﬂuid cells from NC-IVF
and cIVF follicles. There were no signiﬁcant differences
between the two groups.
NC-IVFa (n 5 15) cIVFb (n 5 18)
Mean age (years) 36.1+4.4 (27–42) 35.5+3.8 (27–42)
Anti-Mullerian
hormone (pmol/l)
10.7 (+8.5) 18.5 (+7.6)
Mean follicle size (mm) 18.0 (+1.2) 19.3 (+1.3)
Activity (au) 1360+277 1144+182
aNatural cycle IVF.
bConventional gonadotrophin-stimulated IVF.
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of1.36 (95%CI1.05–178) (Hill et al., 2012). In ﬁve studies comparing the
long GnRH agonist with the GnRH antagonist protocol, the latter
produced a higher implantation rate with an OR of 1.56 (95% CI
1.04–2.33) (Hill et al., 2012).These results are in linewithourhypothesis
as LH concentrations are less suppressed in antagonist protocols than in
long protocols.
Lower apoptosis rates in human cumulus cells in rLH-substituted IVF
cycles also support a positive effect of LH (Ruvolo et al., 2007).Whether
this effect directly or indirectly leads to better granulosa cell function via
an increased androgen production (the consequence ofwhich is possibly
increased AMH production) has not been demonstrated to date;
however, it seems likely to us to play a role.
What implications can be made from our study in the context with
the other clinical studies listed? The present study supports previous
results, this time from an as yet unreported perspective, that high in-
trafollicular AMH and androgen concentrations may be physiological
and therefore can probably be markers for normal follicular function.
Our study also supports the results of the meta-analyses show-
ing that rLH supplementation may be advantageous for follicular
function. According to our investigations, LH probably stimulated the
androgen-AMH-axis.
For future studies, these results indicate that in deﬁned subgroups,
such as older women for example, exogenous LH/hCG supplementa-
tion or decreased suppression of endogenous LH production could be
considered. Using the physiological endocrine proﬁle in naturally
matured follicles as a reference value could also be an advantage.
In summary, the comparison of the endocrine proﬁle of naturally
matured follicles (NC-IVF) with the proﬁle after conventional gonado-
trophin stimulation (cIVF) shows a signiﬁcant suppression of LH, andro-
gen and AMH concentrations after cIVF. A comparison of our results
with those of other clinical studies suggests a negative effect of suppres-
sion of the hypophyseal LH production from cIVF on the follicular endo-
crine system.
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